Kyowa Kirin to offload nartograstim to settle antimonopoly concerns
This article was originally published in Scrip
Kyowa Hakko Kirin is to transfer all Japanese rights to its recombinant granulocyte colony stimulating factor (G-CSF) Neu-up (nartograstim) to fellow Japanese company Yakult Honsha next spring, in a move to resolve antimonopoly concerns.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?